Recent Developments - Roche has made significant progress in diagnostics, drug development, and personnel appointments, with a focus on enhancing its strategic initiatives in China [1] - On February 13, 2026, Roche's VENTANA CLDN18 (43-14A) companion diagnostic was approved by the Chinese regulatory authority, marking it as the first tool for targeted therapy in gastric cancer using trastuzumab, addressing a gap in precision treatment for gastric cancer in China [1] - On February 16/17, 2026, Roche announced that its core product Gazyva/Gazyvaro (obinutuzumab) achieved its primary endpoint in the global Phase III MAJESTY study for primary membranous nephropathy, showing a significantly higher complete remission rate compared to active control, positioning it as a potential first approved drug for this indication [1] - On February 18, 2026, Roche appointed Mark Dawson as the head of the Pharmaceutical Research and Early Development (pRED) department, effective May 1, to strengthen its focus on cutting-edge fields such as epigenetics [1] - Roche emphasized its centennial strategy in China, increasing investments in AI and digital technology applications to support the health goals of the country [1] Stock Performance - Roche's stock price demonstrated a steady upward trend over the past week, with a cumulative increase of 3.08% and a price range fluctuation of 3.75%, reaching a high of $60.22 on February 17 and a low of $58.05 on February 12 [1] - Daily fluctuations included a closing price of $58.61 on February 12 (up 1.42%), $58.51 on February 13 (down 0.17%), $60.10 on February 17 (up 2.72%), and $59.57 on February 18 (down 0.88%) [1] - The stock's five-day change was 4.82%, with a year-to-date increase of 15.51%, despite a low trading volume (average turnover rate of approximately 0.02%), showcasing resilience as the pharmaceutical sector declined by 1.31% and the Nasdaq index fell by 1.82% [1] Institutional Insights - Institutions continue to monitor Roche's pipeline value, with TD Cowen maintaining a "Hold" rating and a target price of $67 as of February 11, 2026, citing advancements in oncology and neuroscience as supporting long-term potential, while also highlighting the need to be aware of patent expiration risks [2]